ABP 300 neutralizes COVID-19 by binding to the receptor binding domain (RBD) of the complex protein SARS-CoV-2, blocking viral interaction with host angiotensin conversion enzyme 2 (ACE2) receptors that are for viral access and infection. With this mechanism of action, ABP 300 not only absolutely neutralizes COVID-19 in animal models, but can also do so in a safer and more effective way than other monoclonal antibodies that are coming.
“The COVID-19 pandemic represents the most urgent global fitness crisis in decades and has presented our industry with the challenge of safely and adequately exploiting new healing goals to treat infections and lessen their effect on patients,” said Ian Chan, CEO and co-founder of Abpro Corporation. “With the final touch of dosing in this Phase 1 trial, we are one step closer to the prospective provision of this first-line treatment for patients with COVID-19 and as a prophylactic for people in good physical shape. We looked forward to presenting the knowledge for this test in the first quarter of 2021. »
The Phase 1 clinical trial is a randomized protective exam that recruited 42 healthy subjects. ABP 300 is being developed in conjunction with Mabwell, a Shanghai-based biotechnology company, where Abpro’s Phase 1 trial is underway. Both companies are using their respective antibody platforms, adding Abpro’s DiversImmune ™ platform to advance the program to patients as temporarily as you can imagine in a number of treatment modalities.
ABP 300 is a human neutralizing monoclonal antibody treatment opposed to COVID-19 that was created with the newest technologies available for antibody discovery. ABP 300 interrupts the interaction of the viral receptor binding domain (RBD) with the host’s angiotensin 2. conversion enzyme receptor (ACE2) and has demonstrated in vivo neutralizing efficacy against COVID-19 by blocking viral access to cells. ABPthreecientos is recently undergoing a phase 1 clinical trial in healthy human subjects.
About Abpro
Abpro Corporation is a clinically level biotechnology company located in Woburn, Massachusetts. The company’s project is for the lives of humanity facing serious and life-threatening diseases through next-generation healing antibodies. Abpro’s DiversImmune ™ platform has been used effectively against 300 difficult targets. The Society has a portfolio of treatments to treat cancer, eyes, autoimmune diseases, infectious diseases and other areas. For more information, visit www. abpro. com.
Media Contact Michael Tattory LifeSci Communications 1 (646) 751-4362mtattory@lifescicomms. com